Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European ...

In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for ...

Moderna, Inc. (NASDAQ:MRNA) is one of the 10 Best Performing American Stocks in June 2026. On July 7, 2026, RBC Capital ...

Moderna's growth story is just beginning.

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In a ...

Moderna has delivered a sharp 148.1% gain year to date, yet its low value score and rich market multiples suggest the stock ...

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant exposure to the U.S. pharmaceutical and biotechnology company. The stock ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Moderna gains fresh market attention after a unanimous flu vaccine panel vote strengthens confidence in its mRNA vaccine ...

Dwight Morrow was thrilled to land a job at Moderna in June 2023 after its blockbuster COVID-19 vaccine had turned the once-obscure Cambridge biotech into a household name. Morrow, a molecular and ...